Ann: FNN Interview and Presentation, page-27

I think it interesting that one of the directors increased his interest through a private company about September 2018. I think the purchases were about $400,000. He must have some confidence.   Technogas has only been used on a limited type of procedure, lung function. From my understanding, ther is now also a market for diagnosis in relation to pulmonary embolism which is quite a separate area. If the approvals come through, the longer terms sales prospects are enhanced.  It seems as if the US FDA approval process is a likely catalyst for increasing sales.